WINNIPEG, Jan. 12, 2009 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the
"Company") today announced the sale of their flagship product, IMRISneuro, to
Yale-New Haven Hospital in New Haven, Connecticut, one of the leading
neuroscience centers in the U.S.
The only one of its kind in the world, IMRISneuro incorporates a movable
high-field MRI with a state-of-the-art integration platform, IMRISmatrix,
allowing the surgical team to scan, view and share critical patient
information during a procedure. At Yale-New Haven Hospital, the IMRISneuro
system will move between two operating theatres and a diagnostic center,
providing leading edge, multi-functional capabilities to the hospital's
"We are confident that in the hands of the surgeons at Yale-New Haven
Hospital, IMRISneuro can make a major contribution towards providing patients
with the highest standard of treatment and care," said David Graves, President
and CEO of IMRIS.
The purchase is contingent upon the receipt of a Certificate of Public
Need from the State of Connecticut.
IMRIS (TSX: IM) is a global leader in providing fully integrated,
advanced surgical imaging solutions. The company's flagship product,
IMRISneuro, utilizes patented technology that allows a high field MRI scanner
to be moved in to the operating room on demand, providing imaging during the
surgical procedure without compromising patient safety. This unique and
innovative system has been validated by leading neurosurgeons for use in
world-class neuroscience centers.
For more information, visit www.imris.com.
For further information:
For further information: Susan McLeod, Manager, Marketing,
Communications, IMRIS Inc., Tel: (204) 480-7094, Email: firstname.lastname@example.org